Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

JOURNAL ARTICLE published December 2018 in Haematologica

Authors: Andrew Spencer | Suzanne Lentzsch | Katja Weisel | Hervé Avet-Loiseau | Tomer M. Mark | Ivan Spicka | Tamas Masszi | Birgitta Lauri | Mark-David Levin | Alberto Bosi | Vania Hungria | Michele Cavo | Je-Jung Lee | Ajay K. Nooka | Hang Quach | Cindy Lee | Wolney Barreto | Paolo Corradini | Chang-Ki Min | Emma C. Scott | Asher A. Chanan-Khan | Noemi Horvath | Marcelo Capra | Meral Beksac | Roberto Ovilla | Jae-Cheol Jo | Ho-Jin Shin | Pieter Sonneveld | David Soong | Tineke Casneuf | Christopher Chiu | Himal Amin | Ming Qi | Piruntha Thiyagarajah | A. Kate Sasser | Jordan M. Schecter | Maria-Victoria Mateos